Mankind Pharma's quarterly profit jumps 39% on strong chronic drug demand

What happened

Mankind Pharma reported second-quarter consolidated net profit rose to 7.11 billion rupees ($74.7 million) from 5.12 billion rupees a year earlier, helped by strong demand for chronic therapies such as diabetes and cardiac treatments.

Confirmed

Global impact / market context

Stronger chronic drug sales lifted domestic revenue 16% to 34.28 billion rupees, with the cardiac segment up 19%. This shows steady demand for long-term treatments can support profit growth even as peers face rising research costs.

Analyst inference

Peer Torrent Pharma reported a near 10% drop in quarterly profit as research and development costs outweighed strong domestic demand. That contrast highlights how cost pressure can offset revenue growth, making Mankind's profit gain notable.

Analyst inference

What to watch

1. Mankind's domestic revenue excluding consumer healthcare grew 16%, led by cardiac growth of 19% and anti-diabetes growth of 16%, showing which therapy areas drove the quarter. Confirmed
2. Investors may compare Mankind's growth with Torrent Pharma, whose profit fell nearly 10% as research and development costs outweighed strong domestic demand. Proposed
3. Watch whether chronic therapy demand keeps supporting revenue and profit, and whether rising research costs similar to Torrent's begin to weigh on Mankind's results. Analyst inference

Evidence

• Original source link unavailable